PCM
GRCE

Prelude Capital Management’s Grace Therapeutics GRCE Stock Holding History

Prelude Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.6K Buy
+10,074
New +$39.6K ﹤0.01% 1130
2019
Q4 		– Sell
-11
Closed -$1K – 2318
2019
Q3 		$1K Buy
+11
New +$1.02K ﹤0.01% 1648

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Prelude Capital Management's GRCE Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 10,074 shares worth $46.6K. The stake represents ﹤0.01% of the portfolio and ranks #1130 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in GRCE as recently as Q3 2019.

Prelude Capital Management first reported a position in GRCE in Q3 2019 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • Prelude Capital Management held 10,074 shares of Grace Therapeutics worth $46.6K as of Q1 2026.
  • Grace Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Grace Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1130 holding.
  • Prelude Capital Management first reported a position in Grace Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.